<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413685</url>
  </required_header>
  <id_info>
    <org_study_id>P071004</org_study_id>
    <nct_id>NCT01413685</nct_id>
  </id_info>
  <brief_title>Calcineurin Activity in Renal Recipients</brief_title>
  <official_title>Interest of Calcineurin Activity for the Therapeutic Tacrolimus Monitoring in Renal Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to define if calcineurin activity is a better biological parameter than blood&#xD;
      concentration for the therapeutic tacrolimus monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some authors showed that the determination of calcineurin (enzyme of cyclosporin and&#xD;
      tacrolimus action) activity was very interesting in bone narrow and hepatic transplant in&#xD;
      order to monitor tacrolimus or cyclosporin. Indeed, Furthermore, target Tac concentrations&#xD;
      still fail to provide in certain patients an appropriate immunosuppression reflected by&#xD;
      rejection. Because a lack of data in renal transplant, we propose to study this population&#xD;
      treated by tacrolimus, mycophenolate mofetil and corticoids in the first three months&#xD;
      following the transplantation.&#xD;
&#xD;
      Our major aim is to study the relationship between calcineurin activity and immunologic&#xD;
      events in 200 renal recipients treated with tacrolimus in the first three months following&#xD;
      transplant. Immunologic events could be acute rejections and infraclinical rejections. The&#xD;
      second aims are 1) if this relationship exists, to define the threshold predicting acute&#xD;
      rejection using ROC-curve, 2) to define variations between pharmacodynamic (calcineurin&#xD;
      activity) and pharmacokinetic (whole blood concentrations) tacrolimus monitoring and 3) to&#xD;
      compare calcineurin activity in patients with acute rejection and those with borderline&#xD;
      rejection. Blood samples will be collected into EDTA-containing vacutainers prior to the&#xD;
      tacrolimus morning administration and at 2, 4, 6 and 9 hours following the administration at&#xD;
      D7, D14 and D21. Whole blood tacrolimus concentrations and calcineurin activity were measured&#xD;
      using LCMSMS and HPLC techniques. After D21, only residual measurements will be carried out&#xD;
      at D28, M2 and M3. A comparative statistical analysis will be performed between data defined&#xD;
      with and without rejection. In case of difference, a ROC curve analysis could define normal&#xD;
      ranges of calcineurin activity.&#xD;
&#xD;
      This is the second study of the Sud FRANCILIEN Institute for Research in&#xD;
      Nephrology-Transplantation defined with Nephrology departments in Mondor and BICETRE&#xD;
      hospitals and the object &quot;Interest of pharmacodynamics of immunosuppressive drugs in&#xD;
      renal-transplant recipients&quot; is a new theme of these teams.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no patient corresponding to criteria&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes</measure>
    <time_frame>at day 8, day15, day21 (pharmacokinetics on 4 times samples), day 28, month 2 and month 3 (residual measurement)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetics (3A5)</measure>
    <time_frame>at day 8, day 15, day 21, day 28, month 2 and month 3</time_frame>
    <description>Genotyping of CYP3A5 * 3 (A6986G) and mdr-1: mutations of these proteins could explain the changes of absorption of tacrolimus.&#xD;
For each patient, during the first month of treatment, 5 ml of blood will be collected on EDTA tube.&#xD;
Genotyping is realized by the allelic discrimination technique Taqman, on a ABI Prism 7000 (TaqMan ®) in the Molecular Biology unit, Pharmacogenetics and Hormonology Bicêtre Hospital</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetics/dynamics</intervention_name>
    <description>Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)</description>
    <arm_group_label>Tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult renal transplant recipients&#xD;
&#xD;
          -  treated by tacrolimus (Prograf or ADVAGRAF), corticoids, Cellcept,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with a high risk of bad compliance (toxicomania, severe psychiatric troubles)&#xD;
&#xD;
          -  multiorgan transplant patients with mTOR inhibitors treatments&#xD;
&#xD;
          -  HIV infected patients&#xD;
&#xD;
          -  lack of consent for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe GRIMBERT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tacrolimus</keyword>
  <keyword>calcineurin</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>TDM</keyword>
  <keyword>pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

